Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01992094 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,680
- Enrollment target
NCT01992094 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 2,680 participants.
The verdict
NCT01992094, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,680 participants
- Enrollment target
Study Summary
Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
Interventions
- BIOLOGICAL QIVc
- BIOLOGICAL TIV1c
- BIOLOGICAL TIV2c
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,680 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01992094
The ClinicalTrials.gov registry entry for NCT01992094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which QIVc is the first listed.
NCT01992094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01992094 about?
NCT01992094 is a clinical study titled "Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older". Evaluate safety and immunogenicity of three influenza vaccines in adults 18 years of age and above.
What is the current status of trial NCT01992094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,680 participants. The study started on 2013-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01992094?
The interventions under investigation include: QIVc (BIOLOGICAL), TIV1c (BIOLOGICAL), TIV2c (BIOLOGICAL).
Who is sponsoring clinical trial NCT01992094?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.